Everything You Need to Know About Leqembi Maintenance and Medicare
After Leqembi removes amyloid plaques from the brain, treatment isn't over. The brain continues to produce beta-amyloid every day, and in Alzheimer's disease a small amount escapes the brain's natural clearance systems. Without continued treatment, these molecules can gradually accumulate again, forming toxic oligomers, protofibrils, and eventually new plaques. This article explains why maintenance therapy is essential after the initial 18 months of Leqembi, compares monthly IV infusions with the FDA-approved IQLIK® self-injection, and provides a practical guide to Medicare Part B and Part D coverage, specialty pharmacies, formularies, prior authorization, and out-of-pocket costs so you can make informed decisions about your long-term treatment options.
How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.
Leqembi Does Much More Than Remove Plaque
Most people think Leqembi simply removes amyloid plaque. The science tells a much bigger story. Researchers now believe tiny beta-amyloid oligomers begin damaging synapses and disrupting the brain's glutamate-GABA balance years before plaques appear. Understanding how Leqembi targets these toxic proteins changed the way I think about Alzheimer's disease, and why early treatment matters.
Alzheimer’s Tau Tangle Challenges
For decades, beta-amyloid plaques have dominated Alzheimer's research, but scientists now believe tau tangles are the primary driver of neuron damage and memory loss. This article explains, in easy-to-understand language, how healthy tau proteins support brain cells, what causes them to become tangled, how they spread from neuron to neuron, and why they remain one of Alzheimer's greatest treatment challenges. Drawing from both the latest scientific discoveries and my personal experience after successfully clearing amyloid plaque with Leqembi, this article also explores the promising new therapies that may one day stop tau tangles and change the future of Alzheimer's disease.
Leqembi IQLIK and Medicare: Everything You Need to Know Before You Switch
Should you stay on Leqembi infusions or switch to the new at-home IQLIK injection? That decision involves much more than convenience. Medicare covers the two treatments differently, and understanding Part B, Part D, specialty pharmacies, formularies, prior authorization, and the new annual out-of-pocket cap can save you both time and money. This practical guide explains the process step by step so people living with early Alzheimer's disease and their caregivers can make informed decisions before their first IQLIK prescription.